MetLife director awarded 169 deferred shares

MetLife Inc. director Diana McKenzie reported an automatic share award linked to deferred compensation.

Rhea-AI Filing Summary

MetLife Inc. director Diana McKenzie reported an automatic share award linked to deferred compensation. She acquired 169 shares of common stock at an imputed price of $85.57 per share through reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this routine compensation-related acquisition, she holds 24,642 shares of MetLife common stock directly.

Insider Trade Summary

Grant/Award: 169 shares

Grant/Award 1 txn

Insider MCKENZIE DIANA

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	169	$85.57	$14K

Holdings After Transaction: Common Stock — 24,642 shares (Direct)

Footnotes (1)

1. F1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Key Figures

Shares acquired: 169 shares Imputed price per share: $85.57 per share Holdings after transaction: 24,642 shares

3 metrics

Shares acquired 169 shares Grant/award acquisition on 2026-06-09

Imputed price per share $85.57 per share Value attributed to the 169-share award

Holdings after transaction 24,642 shares Total MetLife common stock directly held by McKenzie after award

Key Terms

MetLife Deferred Compensation Plan for Non-Management Directors, deferred shares, imputed reinvestment of dividends

3 terms

MetLife Deferred Compensation Plan for Non-Management Directors financial

"Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors."

deferred shares financial

"Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred."

Deferred shares are a class of stock whose economic benefits or certain shareholder rights are delayed or paid later than ordinary shares—for example, dividends may be paid only after other shareholders receive theirs, or voting or redemption rights may be postponed. For investors, that timing difference matters because deferred shares typically offer lower near-term income and different risk, affecting expected returns, priority in payouts, and the share’s market value; think of them like a delayed paycheck compared with a regular salary.

imputed reinvestment of dividends financial

"Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MetLife (MET) director Diana McKenzie report?

Director Diana McKenzie reported acquiring 169 MetLife common shares. The shares were credited as an award tied to deferred compensation, reflecting dividend reinvestment on previously deferred stock, rather than an open-market purchase, and increased her direct holdings to 24,642 shares.

At what price were the new MetLife (MET) shares attributed in this Form 4?

The 169 newly credited MetLife shares were recorded at an imputed price of $85.57 per share. This price is used for reporting the value of the grant tied to dividend reinvestment on deferred shares under the company’s non-management director plan.

How many MetLife (MET) shares does Diana McKenzie hold after this transaction?

After this transaction, Diana McKenzie holds 24,642 MetLife common shares directly. This total reflects her position following the award of 169 shares associated with dividend reinvestment on deferred shares under the director deferred compensation program.

Was Diana McKenzie’s MetLife (MET) Form 4 a market purchase or a compensation award?

The filing reports a compensation-related acquisition, not a market trade. The 169 shares resulted from imputed reinvestment of dividends on deferred shares pursuant to MetLife’s Deferred Compensation Plan for Non-Management Directors, classified as a grant or award acquisition.

What does the MetLife (MET) footnote say about the 169-share acquisition?

The footnote explains the 169 shares came from imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. It notes deferred shares are payable MetLife common stock whose receipt the director has chosen to defer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 04:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCKENZIE DIANA

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NEW YORK 10166

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		A(1)		169	A	$85.57	24,642	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Remarks:

	/s/ Morgan Keehner-Jones Mayes, Attorney-in-fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)